特發性肺纖維化診斷和治療市場 - 預測 2023-2028

特發性肺纖維化診斷和治療市場預計到 2021 年將達到 40.35 億美元，預測期內復合年增長率為 12.58%，到 2028 年將達到 92.49 億美元

本研究報告根據類型和地區的各個細分市場研究了特發性肺纖維化診斷和治療市場。 首先，市場概述詳細介紹了關鍵驅動因素和挑戰。 然後利用波特五力模型全面分析特發性肺纖維化診斷和治療市場。 然後價值鏈分析確定哪些公司屬於不同流程並為不同領域做出貢獻。

它還提供了有關市場發展、趨勢、行業政策以及影響特發性肺纖維化診斷和治療市場的政策的深入信息。 此外，本研究分析了特發性肺纖維化診斷和治療市場的總體監管框架，以便利益相關者更好地了解影響整體市場格局的關鍵因素。

特發性肺纖維化診斷和治療市場 - 預測 2023-2028”是一份全面的更新報告。 我們向管理層和感興趣的利益相關者提供關鍵市場信息，並讓他們了解關鍵市場信息。 我們還分析了主要市場參與者的競爭格局和詳細策略，並將其繪製在我們的供應商矩陣中的四個像限中：領導者、追隨者、挑戰者和利基市場。

內容

第一章簡介

• 市場概覽
• 市場定義
• 調查範圍
• 市場細分
• 貨幣
• 先決條件
• 基準年和預測年時間表

第 2 章研究方法

• 調查數據
• 先決條件

第 3 章執行摘要

• 調查要點

第四章市場動態

• 市場驅動因素
• 市場製約因素
• 波特五力分析
• 行業價值鏈分析

第五章特發性肺纖維化診斷和治療市場：按類型

• 簡介
• 診斷測試
• 藥理學藥物
• 手術治療

第六章特發性肺纖維化診斷和治療市場：按地區

• 簡介
• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 其他
• 中東和非洲
  • 沙特阿拉伯
  • 阿拉伯聯合酋長國
  • 以色列
  • 其他
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 印度尼西亞
  • 泰國
  • 其他

第七章競爭格局與分析

• 主要公司及戰略分析
• 新興公司和市場盈利能力
• 合併、收購、協議與合作
• 供應商競爭力矩陣

第八章公司簡介

• Roche Holding AG
• Boehringer Ingelheim
• AdAlta
• ATS Journals
• Mayo Clinic
• Medscape

The idiopathic pulmonary fibrosis diagnostic and treatment market was valued at US$4.035 billion in 2021 and is projected to expand at a CAGR of 12.58% over the forecast period to reach US$9.249 billion by 2028.

This research study examines the idiopathic pulmonary fibrosis diagnostic and treatment market based on various segments: type and geography. First, a brief overview of the market details key driving factors and challenges. Next, Porter's five forces model analyzes the idiopathic pulmonary fibrosis diagnostic and treatment market comprehensively. This is followed by industry value chain analysis which determines the companies which are part of the different processes and contributing to various sectors.

The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the idiopathic pulmonary fibrosis diagnostic and treatment market. Moreover, the research study analyzes the overall regulatory framework of the idiopathic pulmonary fibrosis diagnostic and treatment market, offering stakeholders a better understanding of the key factors influencing the overall market environment.

Idiopathic pulmonary fibrosis diagnostic and treatment market - Forecasts from 2023 to 2028 is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape and details strategies of key market players and also plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.

The scope and coverage of the idiopathic pulmonary fibrosis diagnostic and treatment market report is as below:

• Idiopathic pulmonary fibrosis diagnostic and treatment market data tables and charts
• Market outlook with sections on drivers, restraints, Porter's and industry value chain analysis
• Market assessment by type into diagnostic testing, pharmacological drugs, and surgical treatment.
• A 360° view of the demand for idiopathic pulmonary fibrosis diagnostic and treatment market solutions/services across different geographies (North America, South America, Europe, Middle East and Africa, and Asia Pacific) with further breakdown for key countries within those regions.

Different segments covered under the idiopathic pulmonary fibrosis diagnostic and treatment market report are as below:

By Type

• Diagnostic Testing
• Pharmacological Drugs
• Surgical Treatment

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Diagnostic Testing
• 5.3. Pharmacological Drugs
• 5.4. Surgical Treatment

6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET, BY GEOGRAPHY

• 6.1. Introduction
• 6.2. North America
  • 6.2.1. United States
  • 6.2.2. Canada
  • 6.2.3. Mexico
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Argentina
  • 6.3.3. Others
• 6.4. Europe
  • 6.4.1. United Kingdom
  • 6.4.2. Germany
  • 6.4.3. France
  • 6.4.4. Spain
  • 6.4.5. Others
• 6.5. The Middle East and Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. Israel
  • 6.5.4. Others
• 6.6. Asia Pacific
  • 6.6.1. Japan
  • 6.6.2. China
  • 6.6.3. India
  • 6.6.4. South Korea
  • 6.6.5. Indonesia
  • 6.6.6. Thailand
  • 6.6.7. Others

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 7.1. Major Players and Strategy Analysis
• 7.2. Emerging Players and Market Lucrativeness
• 7.3. Mergers, Acquisitions, Agreements, and Collaborations
• 7.4. Vendor Competitiveness Matrix

8. COMPANY PROFILES

• 8.1. Roche Holding AG
• 8.2. Boehringer Ingelheim
• 8.3. AdAlta
• 8.4. ATS Journals
• 8.5. Mayo Clinic
• 8.6. Medscape